{(E)-2-[3,5-bis(trifluoromethyl)phenyl]vinyl}boronic acid | 1144505-36-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {(E)-2-[3,5-bis(trifluoromethyl)phenyl]vinyl}boronic acid
• 英文别名: trans-2-[3,5-bis(trifluoromethyl)phenyl]vinylboronic acid；trans-2-(3,5-Bis-trifluoromethylphenyl)-vinyl-boronic acid；[(E)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]boronic acid
• CAS: 1144505-36-1
• 化学式: C₁₀H₇BF₆O₂
• 分子量: 283.966
• InChiKey: DEPLVQQDXMABMJ-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.75
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  {(E)-2-[3,5-bis(trifluoromethyl)phenyl]vinyl}boronic acid 在 四(三苯基膦)钯 、 potassium tert-butylate 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 5.5h， 生成 3,4-bis(benzyloxy)-6-[(E)-2-[3,5-bis(trifluoromethyl)phenyl]-ethenyl]pyridazine
  参考文献：
  名称：

  4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors

  摘要：

  D-Amino acid oxidase (DAAO) catalyzes the oxidation of D-amino acids including D-serine, a coagonist of the N-methyl-D-aspartate receptor. We identified a series of 4-hydroxypyridazin-3(2H)-one derivatives as novel DAAO inhibitors with high potency and substantial cell permeability using fragment-based drug design. Comparisons of complex structures deposited in the Protein Data Bank as well as those determined with in-house fragment hits revealed that a hydrophobic subpocket was formed perpendicular to the flavin ring by flipping Tyr224 in a ligand-dependent manner. We investigated the ability of the initial fragment hit, 3-hydroxy-pyridine-2(1H)-one, to fill this subpocket with the aid of complex structure information. 3-ydroxy-5-(2-phenylethyl)pyridine-2(1H)-one exhibited the predicted binding mode and demonstrated high inhibitory activity for human DAAO in enzyme- and cell-based assays. We further designed and synthesized 4-hydroxypyridazin-3(2H)-one derivatives, which are equivalent to the 3-hydroxy-pyridine-2(1H)-one series but lack cell toxicity. 6-[2-(3,5-Difluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one was found to be effective against MK-801-induced cognitive deficit in the Y-maze.

  DOI：

  10.1021/jm400095b
• 作为产物：
  描述：

  3,5-双三氟甲基苯乙炔 、 儿萘酚硼烷 以 四氢呋喃 为溶剂， 反应 17.0h， 以34%的产率得到{(E)-2-[3,5-bis(trifluoromethyl)phenyl]vinyl}boronic acid
  参考文献：
  名称：

  [EN] NOVEL CAPSAICIN ANALOGS AND USES THEREOF
  [FR] NOUVEAUX ANALOGUES DE CAPSAÏCINE ET LEURS UTILISATIONS

  摘要：

  本发明提供包含化合物（I）、（II）或（III）的组合物，以及使用它们治疗各种疾病的方法，包括神经系统疾病、癌症、糖尿病和肥胖症，其中在（I）中R1-R7，X，A和Q，在（II）中R1-R15，在（III）中R1-R15的定义如本文所述。在某些实施例中，治疗各种疾病，包括疼痛和癌症的方法，包括将化合物（I）、（II）或（III）的治疗有效量局部、局部或全身（例如静脉注射、腹腔注射或口服）给需要的患者。

  公开号：

  WO2022099284A1

文献信息

• CARBON LINKED MODULATORS OF gamma-SECRETASE
  申请人：HO Chih Yung

  公开号：US20090105288A1

  公开（公告）日：2009-04-23

  The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.

  本发明涉及以下式子中的化合物I，其中在说明书中提供了A、X、R1、R3、R4、R5、R6、R7、R8和R9的定义。式I的化合物对于治疗与γ-分泌酶活性有关的疾病，包括阿尔茨海默病，具有用途。
• Carbon linked modulators of gamma-secretase
  申请人：Ho Chih Yung

  公开号：US08692017B2

  公开（公告）日：2014-04-08

  The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.

  本发明涉及以下式子的化合物I，其中A，X，R1，R3，R4，R5，R6，R7，R8和R9的定义在说明书中提供。式I的化合物对于治疗与γ-分泌酶活性相关的疾病，包括阿尔茨海默病，是有用的。
• 4-Hydroxypyridazin-3(2<i>H</i>)-one Derivatives as Novel <scp>d</scp>-Amino Acid Oxidase Inhibitors
  作者：Takeshi Hondo、Masaichi Warizaya、Tatsuya Niimi、Ichiji Namatame、Tomohiko Yamaguchi、Keita Nakanishi、Toshihiro Hamajima、Katsuya Harada、Hitoshi Sakashita、Yuzo Matsumoto、Masaya Orita、Makoto Takeuchi

  DOI：10.1021/jm400095b

  日期：2013.5.9

  D-Amino acid oxidase (DAAO) catalyzes the oxidation of D-amino acids including D-serine, a coagonist of the N-methyl-D-aspartate receptor. We identified a series of 4-hydroxypyridazin-3(2H)-one derivatives as novel DAAO inhibitors with high potency and substantial cell permeability using fragment-based drug design. Comparisons of complex structures deposited in the Protein Data Bank as well as those determined with in-house fragment hits revealed that a hydrophobic subpocket was formed perpendicular to the flavin ring by flipping Tyr224 in a ligand-dependent manner. We investigated the ability of the initial fragment hit, 3-hydroxy-pyridine-2(1H)-one, to fill this subpocket with the aid of complex structure information. 3-ydroxy-5-(2-phenylethyl)pyridine-2(1H)-one exhibited the predicted binding mode and demonstrated high inhibitory activity for human DAAO in enzyme- and cell-based assays. We further designed and synthesized 4-hydroxypyridazin-3(2H)-one derivatives, which are equivalent to the 3-hydroxy-pyridine-2(1H)-one series but lack cell toxicity. 6-[2-(3,5-Difluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one was found to be effective against MK-801-induced cognitive deficit in the Y-maze.
• [EN] NOVEL CAPSAICIN ANALOGS AND USES THEREOF<br/>[FR] NOUVEAUX ANALOGUES DE CAPSAÏCINE ET LEURS UTILISATIONS
  申请人：YOUNG BIOPHARMA LLC

  公开号：WO2022099284A1

  公开（公告）日：2022-05-12

  The present invention provides compositions comprising compounds having formulas (I), (II) or (III): and additionally provides methods for the use thereof in the treatment of various disorders including neurological disorders, cancer, diabetes, and obesity, wherein R1-R7, X, A, and Q in (I), R1-R15 in (II) and R1-R15 in (III) are as defined herein. In certain embodiments, methods for the treatment of various disorders including pain and cancer comprise topically, locally or systemically (e.g., IV, IP or orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formulas (I), (II) or (III).

  本发明提供包含化合物（I）、（II）或（III）的组合物，以及使用它们治疗各种疾病的方法，包括神经系统疾病、癌症、糖尿病和肥胖症，其中在（I）中R1-R7，X，A和Q，在（II）中R1-R15，在（III）中R1-R15的定义如本文所述。在某些实施例中，治疗各种疾病，包括疼痛和癌症的方法，包括将化合物（I）、（II）或（III）的治疗有效量局部、局部或全身（例如静脉注射、腹腔注射或口服）给需要的患者。